Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial (2020) Multhoff G, Seier S, Stangl S, Sievert W, Shevtsov M, Werner C, Pockley AG, et al. Journal article Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI). (2020) Rogiers A, Tondini C, Grimes JM, Trager MH, Nahm S, Zubiri L, Papneja N, et al. Conference contribution A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2(-) Primary Breast Cancer (2020) Robertson JFR, Evans A, Henschen S, Kirwan CC, Jahan A, Kenny LM, Dixon JM, et al. Journal article Profiling intratumoral heterogeneity of bladder cancer subtypes at the single-cell level using machine-learning assisted histopathology. (2020) Van Rhijn B, Mertens L, Mayr R, Bostrom P, Marques M, Van Leenders G, Gotz S, et al. Conference contribution Uninflamed immunologic microenvironment of muscle-invasive bladder cancer associates with activating FGFR3 gene alterations. (2020) Weyerer V, Stöhr R, Strissel P, Strick R, Bolenz C, Hartmann A, Erben P, Eckstein M Conference contribution Germline mutations in new susceptibility genes for non-high-grade serous ovarian cancer. (2020) Pavanello M, Dicks E, Song H, Ariff A, Bolithon A, Intermaggio MP, Pinese M, et al. Conference contribution Early Mortality of Brain Cancer Patients and its Connection to Cytomegalovirus Reactivation During Radiochemotherapy (2020) Goerig N, Frey B, Korn K, Fleckenstein B, Überla K, Schmidt M, Dörfler A, et al. Journal article Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE) (2020) Talhouk A, George J, Wang C, Budden T, Tan TZ, Chiu DS, Kommoss S, et al. Journal article Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α (2020) Ingle JN, Cairns J, Suman VJ, Shepherd LE, Fasching P, Hoskin TL, Singh RJ, et al. Journal article A small hypoxia signature predicted pCR response to bevacizumab in the neoadjuvant GeparQuinto breast cancer trial (2020) Karn T, Meissner T, Weber KE, Solbach C, Denkert C, Engels K, Fasching P, et al. Journal article